Top

Published in:

01-12-2008 | Review

Demographics, guidelines, and clinical experience in severe community-acquired pneumonia

Author: Jordi Rello

Published in: Critical Care | Special Issue 6/2008

Abstract

Mortality in patients with community-acquired pneumonia (CAP) who require intubation or support with inotropes in an intensive care unit setting remains extremely high (up to 50%). Systematic use of objective severity-of-illness criteria, such as the Pneumonia Severity Index (PSI), British Thoracic Society CURB-65 (an acronym meaning Confusion, Urea, Respiratory rate, Blood pressure, age ≥65 years), or criteria developed by the Infectious Diseases Society of America/American Thoracic Society, to aid site-of-care decisions for pneumonia patients is emerging as a step forward in patient management. Experience with the Predisposition, Infection, Response, and Organ dysfunction (PIRO) score, which incorporates key signs and symptoms of sepsis and important CAP risk factors, may represent an improvement in staging severe CAP. In addition, it has been suggested that implementing a simple care bundle in the emergency department will improve management of CAP, using five evidence-based variables, with immediate pulse oxymetry and oxygen assessment as the cornerstone and initial step of treatment.

Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG, Infectious Diseases Society of America; American Thoracic Society: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(suppl 2):S27-S72. 10.1086/511159CrossRefPubMed

Kamath AV, Myint PK: Recognising and managing severe community acquired pneumonia. Br J Hosp Med 2006, 26: 76-78.CrossRef

Oosterheert JJ, Bonten MJ, Hak E, Schneider MM, Hoepelman AI: Severe community-acquired pneumonia: what's in a name? Curr Opin Infect Dis 2003, 16: 153-159.CrossRefPubMed

Marrie TJ, Shariatzadeh MR: Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore) 2007, 86: 103-111. 10.1097/MD.0b013e3180421c16CrossRef

Rodríguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Solé-Violán J, Rello J, CAPUCI Study Group: Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007, 35: 1493-1498. 10.1097/01.CCM.0000266755.75844.05CrossRefPubMed

National Center for Health Statistics: Health Statistics, 2006.[http://www.cdc.gov/nchs/fastats]

Bauer TT, Welte T, Ernen C, Schlosser BM, Thate-Waschke I, de Zeeuw J, Schultze-Werninghaus G: Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005, 128: 2238-2246. 10.1378/chest.128.4.2238CrossRefPubMed

España PP, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M, Bilbao A, Quintana JM: Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006, 174: 1249-1256. 10.1164/rccm.200602-177OCCrossRefPubMed

Ewig S, de Roux A, Bauer T, García E, Mensa J, Niederman M, Torres A: Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004, 59: 421-427. 10.1136/thx.2003.008110PubMedCentralCrossRefPubMed

10.

Riley PD, Aronsky D, Dean NC: Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. Crit Care Med 2004, 32: 2398-2402. 10.1097/01.CCM.0000147443.38234.D2CrossRefPubMed

11.

Woodhead MA, Macfarlane JT, Rodgers FG, Laverick A, Pilkington R, Macrae AD: Aetiology and outcome of severe community-acquired pneumonia. J Infect 1985, 10: 204-210. 10.1016/S0163-4453(85)92463-6CrossRefPubMed

12.

Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P: Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest 1994, 105: 1487-1495. 10.1378/chest.105.5.1487CrossRefPubMed

13.

Leroy O, Saux P, Bedos JP, Caulin E: Comparison of lev-ofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005, 128: 172-183. 10.1378/chest.128.1.172CrossRefPubMed

14.

Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, Fine MJ, Singer DE, Kapoor WN: Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002, 166: 717-723. 10.1164/rccm.2102084CrossRefPubMed

15.

Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH: Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000, 90: 223-229. 10.2105/AJPH.90.2.223PubMedCentralCrossRefPubMed

16.

National Center for Health Statistics: Leading causes of death, 1900–1998.[http://www.cdc.gov/nchs/fastats/lcod.htm]

17.

Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG: Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006, 10(suppl 2):S1. 10.1186/cc4927PubMedCentralCrossRefPubMed

18.

Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, Linde-Zwirble WT: Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002, 165: 766-772.CrossRefPubMed

19.

Mandell LA: Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am 2004, 18: 761-776. vii. 10.1016/j.idc.2004.08.003CrossRefPubMed

20.

Neuhaus T, Ewig S: Defining severe community-acquired pneumonia. Med Clin North Am 2001, 85: 1413-1425. 10.1016/S0025-7125(05)70388-6CrossRefPubMed

21.

Rello J, Bodi M, Mariscal D, Navarro M, Diaz E, Gallego M, Valles J: Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003, 123: 174-180. 10.1378/chest.123.1.174CrossRefPubMed

22.

Feldman C, Viljoen E, Morar R, Richards G, Sawyer L, Goolam Mahomed A: Prognostic factors in severe community-acquired pneumonia in patients without co-morbid illness. Respirology 2001, 6: 323-330. 10.1046/j.1440-1843.2001.00352.xCrossRefPubMed

23.

Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A: Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007, 101: 2139-2144. 10.1016/j.rmed.2007.05.011CrossRefPubMed

24.

Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J, de la Torre MV, Sirvent JM, Bodi M: Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006, 27: 1210-1216. 10.1183/09031936.06.00139305CrossRefPubMed

25.

Lisboa T, Blot S, Waterer GW, Canalis E, de Mendoza D, Rodriguez A, Rello J, Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators: Radiological progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest 2008, in press.

26.

Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336: 243-250. 10.1056/NEJM199701233360402CrossRefPubMed

27.

Lim WS, Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58: 377-382. 10.1136/thorax.58.5.377PubMedCentralCrossRefPubMed

28.

Spindler C, Ortqvist A: Prognostic score systems and community-acquired bacteraemic pneumococcal pneumonia. Eur Respir J 2006, 28: 816-823. 10.1183/09031936.06.00144605CrossRefPubMed

29.

Schaaf B, Kruse J, Rupp J, Reinert RR, Droemann D, Zabel P, Ewig S, Dalhoff K: Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia. Eur Respir J 2007, 30: 517-524. 10.1183/09031936.00021007CrossRefPubMed

30.

Christ-Crain M, Morgenthaler NG, Stolz D, Müller C, Bingisser R, Harbarth S, Tamm M, Struck J, Bergmann A, Müller B: Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006, 10: R96. 10.1186/cc4443PubMedCentralCrossRefPubMed

31.

Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174: 84-93. 10.1164/rccm.200512-1922OCCrossRefPubMed

32.

Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC: Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest 2006, 129: 968-978. 10.1378/chest.129.4.968CrossRefPubMed

33.

Marshall JC: Biomarkers of sepsis. Curr Infect Dis Rep 2006, 8: 351-357. 10.1007/s11908-006-0045-1CrossRefPubMed

34.

Opal SM: Concept of PIRO as a new conceptual framework to understand sepsis. Pediatr Crit Care Med 2005, 6(suppl):S55-S60. 10.1097/01.PCC.0000161580.79526.4CCrossRefPubMed

35.

Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC, GenIMS Investigators: Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007, 167: 1655-1663. 10.1001/archinte.167.15.1655PubMedCentralCrossRefPubMed

36.

Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink R: Assessment of severity in ICU patients with community-acquired pneumonia using PIRO score. Crit Care Med 2008.

37.

Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW, Pierce RJ, Armstrong JG, Korman TM, Holmes P, Obrosky DS, Peyrani P, Johnson B, Hooy M, Australian Community-Acquired Pneumonia Study Collaboration, Grayson ML: SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008, 47: 375-384. 10.1086/589754CrossRefPubMed

38.

Blot SI, Rodriguez A, Solé-Violán J, Blanquer J, Almirall J, Rello J, Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators: Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med 2007, 35: 2509-2514. 10.1097/01.CCM.0000266825.19629.BACrossRefPubMed

39.

Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG: Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004, 164: 637-644. 10.1001/archinte.164.6.637CrossRefPubMed

40.

Barlow G, Nathwani D, Myers E, Sullivan F, Stevens N, Duffy R, Davey P: Identifying barriers to the rapid administration of appropriate antibiotics in community-acquired pneumonia. J Antimicrob Chemother 2008, 61: 442-451. 10.1093/jac/dkm462CrossRefPubMed

41.

Bodí M, Rodríguez A, Solé-Violán J, Gilavert MC, Garnacho J, Blanquer J, Jimenez J, de la Torre MV, Sirvent JM, Almirall J, Doblas A, Badía JR, García F, Mendia A, Jordá R, Bobillo F, Vallés J, Broch MJ, Carrasco N, Herranz MA, Rello J, Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators: Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 2005, 41: 1709-1716. 10.1086/498119CrossRefPubMed

42.

Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J: Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit Care Med 2004, 32: 625-631. 10.1097/01.CCM.0000114817.58194.BFCrossRefPubMed

43.

Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34: 1589-1596. 10.1097/01.CCM.0000217961.75225.E9CrossRefPubMed

44.

Orrick JJ, Segal R, Johns TE, Russell W, Wang F, Yin DD: Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to Infectious Diseases Society of America guidelines. Pharmacoeconomics 2004, 22: 751-757. 10.2165/00019053-200422110-00005CrossRefPubMed

45.

Shorr AF, Bodi M, Rodriguez A, Sole-Violan J, Garnacho-Montero J, Rello J, CAPUCI Study Investigators: Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest 2006, 130: 93-100. 10.1378/chest.130.1.93PubMed

Title: Demographics, guidelines, and clinical experience in severe community-acquired pneumonia
Author: Jordi Rello
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Critical Care / Issue Special Issue 6/2008
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc7025

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Demographics, guidelines, and clinical experience in severe community-acquired pneumonia

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 6/2008

Tissue factor as an initiator of coagulation and inflammation in the lung

The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy

Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition

Severe community acquired pneumonia update: mortality, mechanisms and medical intervention